Genicular Artery Embolization (GAE) – A Breakthrough Treatment for Knee Osteoarthritis Pain

Knee osteoarthritis (OA) remains a leading cause of chronic pain and disability worldwide. In fact, the lifetime risk of developing symptomatic knee OA is estimated at 40–47%[1]. Traditional treatment options range from conservative measures (like physical therapy and injections) to total knee replacement surgery, with very little in between. Many patients suffer from persistent knee pain despite maximum medical therapy but are not ready or eligible for major surgery, leaving a significant treatment gap[2][3].

One of the most exciting developments to bridge this gap is Genicular Artery Embolization (GAE) – a minimally invasive, image-guided procedure that targets the inflamed knee joint lining to relieve pain. GAE is reshaping how interventional radiologists, pain specialists, and orthopedic surgeons approach chronic knee pain from osteoarthritis. Below, we provide a comprehensive overview of GAE, including the scientific rationale, evidence from randomized trials, patient selection, and how it compares to other treatments.

How Does Knee Osteoarthritis Cause Pain? (Rationale & Pathophysiology)

Osteoarthritis is not just a “wear-and-tear” disease – inflammation plays a key role in OA pain[4]. In moderate to severe knee OA, the synovium (joint lining) becomes chronically inflamed and sprouts abnormal new blood vessels (a process called angiogenesis). These fragile, abnormal vessels form a web around the knee (genicular arteries) and are accompanied by new sensory nerves and inflammatory cells[4]. This network pumps inflammatory mediators into the joint and sensitizes nerve endings, creating a vicious cycle of pain and swelling. The increased blood flow also contributes to synovial hypertrophy (thickening of the lining) and can accelerate cartilage and bone deterioration[5][6].

Genicular Artery Embolization targets this inflammatory pathway directly. In GAE, a microcatheter is used to deliver tiny particles to block these abnormal neovessels while preserving the normal circulation to the knee. By “shutting off” the hypervascular synovial tissue, GAE reduces the delivery of inflammatory cytokines and effectively “starves” the pain-generating synovium of its blood supply[5]. This leads to decreased inflammation and pain without harming the healthy parts of the joint. Importantly, studies have confirmed that while GAE causes regression of inflamed synovial tissue, it does not cause osteonecrosis (bone death) or cartilage injury – normal vessels to bone and cartilage remain open[7]. In essence, GAE is a precision treatment: it selectively prunes the pathological blood vessels causing pain, breaking the cycle of inflammation and pain signaling.

The GAE Procedure: How It’s Performed and Safety Profile

Procedural angiograms of the knee before (a) and after (b) genicular artery embolization. In the left image, an abnormal hypervascular “blush” (dark tangle of vessels) is seen around the knee joint. The right image is after embolization, showing the disappearance of the pathologic vessels while main arteries remain intact[8][9].

GAE is performed by an interventional radiologist in an angiography suite, usually as an outpatient procedure. It typically takes about 60–90 minutes and is done with conscious sedation (relaxed but awake) or light anesthesia[10]. Here’s an overview of the procedure steps:

• Arterial Access: A tiny pinhole incision is made, usually in the groin (femoral artery) or wrist (radial artery). A small catheter is threaded into the arterial system under live X-ray guidance and navigated to the arteries supplying the knee (the genicular arteries)[11].
• Angiography: Contrast dye is injected to map out the knee’s blood supply. The inflamed synovium shows up as a dense blush of tiny vessels on angiography[8]. The doctor identifies which genicular artery branches feed these hypervascular areas.
• Selective Embolization: Using a microcatheter (about the size of spaghetti), the interventionalist selectively cannulates the abnormal branches. Microscopic particles (100–300 micron microspheres or other agents) are slowly injected until the pathological blush disappears. Care is taken to preserve overall blood flow in the main arteries – only the small, inflamed branches are occluded. Techniques like ice packs on the knee (to induce vasospasm) and tiny doses of nitroglycerin can help prevent non-target embolization of normal tissue.
• Completion: Once all targeted vessels are embolized (on average 2–3 arteries per knee), a final angiogram confirms “pruning” of the abnormal vessels and intact flow through the normal arterial tree. The catheter is removed, and a bandage or closure device is placed.

After a brief recovery (usually 2–4 hours of observation), patients go home the same day. There are no incisions on the knee itself – just the tiny puncture at the access site.

Safety: GAE has an excellent safety profile. Across published studies and trials, no major adverse events have been reported[12]. The most common side effects are mild and self-limited, such as:

• Post-embolization syndrome: some patients experience transient low-grade fever, knee ache, or fatigue in the first few days after the procedure[13][14]. This is managed with rest and anti-inflammatories and typically resolves quickly.
• Skin discoloration or warmth: small patches of redness or warmth around the knee or foot can occur from altered blood flow; these also resolve on their own[13].
• Bruising or hematoma at the catheter entry site (groin or wrist) – a small blood bruise is possible, as with any arterial puncture[15].
• Numbness/tingling: Rarely, if very small particles reach a skin nerve, a temporary numb spot can occur. Using slightly larger particle sizes (>75 µm) helps avoid this[16].

Crucially, studies using MRI after GAE find no evidence of cartilage damage, no cases of osteonecrosis, and no rapid progression of arthritis[7]. The normal blood supply to bone is preserved[7]. In one trial, MRIs at 1 year post-GAE confirmed no structural harm and even showed reduced synovitis (inflammation) compared to before treatment[7]. Overall, GAE is considered very safe and well-tolerated, especially compared to surgical alternatives. Patients typically resume normal activities within a day or two and often start feeling pain relief within the first couple of weeks (sometimes even within days) [17].

Does GAE Work? – Evidence from Studies and Trials

GAE is a relatively new procedure (first used for knee OA pain around 2015), but a growing body of evidence – including randomized controlled trials (RCTs) – supports its effectiveness. Below we summarize key studies and outcomes:

• Initial Japanese Study (2017): In a landmark prospective trial, Okuno et al. treated 72 patients (95 knees) with moderate knee OA and chronic pain[18]. Abnormal neovessels were found in all cases during angiography[19], confirming that synovial angiogenesis is common in OA. Pain and function improved significantly after GAE: average WOMAC pain scores dropped by >50% within 1 month and continued to improve through 6, 12, and 24 months[19]. Impressively, about 80% of patients had sustained pain relief at 3 years after a single GAE treatment[7]. Follow-up MRIs at 2 years showed reduced synovitis and no adverse structural changes[20][7]. This long-term data suggests GAE’s benefits can be durable for the majority of responders.
• Bagla et al. Multicenter RCT (USA, 2022): This was the first randomized, sham-controlled trial of GAE. Twenty-one patients with moderate knee OA pain were randomized 2:1 to GAE vs a sham procedure[21]. The sham group had an angiogram but no particles delivered (and were blinded). The results at 1 month were dramatic: the GAE group’s pain (VAS) dropped about 50 mm more than the sham group on a 0–100 scale[22] – roughly a 50–55% pain reduction in the first month. Functional scores (WOMAC) also improved significantly more with GAE[12]. All patients in the sham arm had little to no improvement at 1 month and elected to crossover to actual treatment[23][22]. By 12 months, the originally treated patients maintained their improvement, and sensitivity analysis (including those who crossed over) still showed significant pain and disability improvement out to 1 year[12]. Notably, only minor side effects occurred in this study[24]. This trial – sometimes referred to as the “EUREKA” study – provided Level I evidence that GAE yields true pain relief beyond any placebo effect in knee OA.
• Japanese Sham-Controlled RCT (Okuno et al., 2021): A sham-controlled trial in Asia (published 2021) similarly reported positive outcomes. By 1 month post-procedure, the GAE-treated patients achieved about a 50% reduction in pain scores, whereas the sham patients did not improve. The benefits of GAE were sustained at 1-year follow-up in the treatment group[12]. (This aligns with the Bagla trial findings, although details of the Japanese RCT are often referenced in summaries of GAE evidence.)
• Landers et al. RCT (Australia, 2023): This triple-blind RCT of 58 patients with early-stage knee OA had an interesting finding. Overall, at 1 month, GAE and sham had similar modest pain improvements (no significant difference) – highlighting that in milder OA, the placebo effect can be strong[25][26]. However, the authors discovered a critical insight: many GAE patients had only “partial” embolization (not all target vessels were fully embolized). In a subgroup analysis, those who received complete embolization of all abnormal vessels had significantly greater improvements in knee pain (KOOS scores) than the sham group (p = 0.012)[26]. Their median KOOS pain score improved from 47 to 72 (out of 100) after GAE[27]. This suggests technique matters – when GAE is done thoroughly, outcomes are better. It also reinforces that careful patient selection (those with active inflammation to treat) is important. By 12 months, in this study, the GAE group (especially fully embolized cases) maintained superior pain relief (KOOS pain 41% improvement vs ~29% in controls)[28]. No safety issues were noted (MRI at 1 year showed no osteonecrosis or cartilage loss)[25].
• Netherlands Sham RCT (van Zadelhoff et al., BMJ Open 2024): A recently published trial of 58 patients with mild-to-moderate OA found no statistically significant difference between GAE and sham at 4 months[29]. Both groups had a moderate pain reduction (~21 points in GAE vs 18 points in sham on a 0–100 scale)[30]. The authors concluded that GAE did not outperform placebo in that timeframe[31]. It’s worth noting, however, that this study’s patients had relatively mild OA pain (and possibly less synovial angiogenesis), and the follow-up was only 4 months. No serious adverse events occurred, though minor side effects were more frequent in the GAE group[32]. The mixed result of this trial underscores the need to identify which patients benefit most and to observe outcomes over a longer term. Other trials (as above) with slightly more advanced disease or longer follow-up did show clear benefits from GAE.
• Systematic Reviews and Meta-Analyses: Multiple reviews have synthesized the data on GAE:
• A 2021 meta-analysis of 11 studies (268 knees) concluded that GAE provides significant pain relief, often within the first week, and can reduce patients’ need for pain medication[33]. The authors noted GAE is a reasonable and safe option to improve function and quality of life in knee OA[33].
• A 2020 qualitative review by Casadaban et al. found that pain scores consistently decreased from as early as 1 day post-GAE to as far as 2 years after the procedure[34]. Patients with mild-to-moderate OA experienced the most durable improvement, whereas those with very severe OA saw more short-lived benefit (pain reduction at 1 month that was not always sustained at 6 months)[35]. This suggests GAE works best in moderate disease, whereas end-stage “bone-on-bone” arthritis may eventually overwhelm the benefits.
• A 2023 systematic review (Taslakian et al.) observed that patients with higher baseline pain (VAS >50) tend to have a greater response to GAE – i.e., those truly suffering tend to gain the most relief[36]. Another recent comprehensive review (Poursalehian et al., 2023) confirmed a consistent decrease in pain scores across all studies, with maximal improvements typically seen between 1 and 4 months post-GAE[37]. Most patients maintained significant relief at 1 year, and a substantial subset continued to feel benefits at 2 years and beyond[38][17].

In summary, the evidence indicates that GAE can produce meaningful, long-lasting pain relief for a large proportion of patients with knee osteoarthritis. We now have Level I evidence of efficacy (from sham-controlled trials)[12], numerous supportive cohort studies, and up to 3–4 year follow-up data in some cases[7]. Patients often report not only less pain, but also improvements in stiffness and functional ability (measured by WOMAC and KOOS scores) after GAE[39][40]. It’s important to acknowledge that not every patient responds – roughly 15–20% may not get significant relief or may have pain return within a year[38]. But about 80% of patients achieve clinically significant pain reduction, and the majority maintain that improvement for at least 1–2 years, with some still doing well at 3+ years[7]. Research is ongoing, including larger multi-center trials and studies to determine optimal technique and patient selection criteria.

Who Is an Ideal Candidate for GAE? (Patient Selection)

GAE is best suited for patients in the “treatment gap” of knee osteoarthritis – those who have chronic moderate knee pain despite conservative treatments, but either do not yet require a knee replacement or cannot undergo surgery for various reasons. In clinical practice, we typically consider GAE for patients with Kellgren–Lawrence grade 2 or 3 OA (mild-to-moderate severity on X-rays) who have persistent pain affecting their quality of life[41][42]. Key points on patient selection:

• Failed Conservative Therapy: Ideal candidates have tried standard measures for at least 3–6 months without adequate relief[41]. This includes weight loss, physical therapy, activity modifications, braces, and medications (NSAIDs, acetaminophen). Many have also tried steroid injections or hyaluronic acid visco-supplementation with little or temporary benefit.
• Severity of Arthritis: Moderate OA (KL 2–3) tends to respond best to GAE[42]. These patients often have significant synovial inflammation (which GAE targets) but are not completely bone-on-bone yet. Patients with very advanced OA (KL 4), who have “bone-on-bone” changes, can still get pain improvement from GAE – and indeed some do – but studies suggest their results are less robust or shorter-lived on average. In those end-stage cases, the pain may be driven more by mechanical bone friction (which GAE can’t fix) rather than inflammation. Nonetheless, GAE can be considered to buy time or reduce pain in severe OA patients who cannot have surgery immediately.
• Surgery Contraindicated or Delayed: GAE is particularly attractive for patients who cannot undergo knee replacement due to medical comorbidities (e.g., uncontrolled cardiac issues, obesity, etc.), or those who wish to delay surgery. For example, a relatively young patient in their 50s with OA may want to postpone joint replacement to avoid multiple revisions later – GAE could help manage pain in the interim. Elderly patients with too many risks for surgery are also good candidates, as GAE is low-risk and can be done under light sedation.
• Inflammatory Signs: On exam or MRI, if a patient has signs of active synovitis (e.g., recurrent swelling, warmth, pain worse with activity, and some rest pain), they are likely to benefit from GAE. Conversely, if a patient’s main issue is mechanical (locking, instability, large bone spurs), other interventions might be needed in addition/instead. That said, most OA pain has an inflammatory component, and GAE specifically addresses that.
• Prior Treatments: Having had prior injections or arthroscopy does not preclude GAE. However, if a patient recently had a corticosteroid injection, the physician might wait a few weeks for that to wear off before evaluating for GAE (to better gauge baseline pain). Patients with genicular nerve ablation (radiofrequency) can still get GAE in the future, and vice versa – the two can be complementary since one targets nerves and the other targets vessels.
• Exclusion Factors: GAE is not suitable if there is an alternative cause of knee pain that should be addressed first. For example, knee pain from rheumatoid arthritis (a systemic inflammatory disease) is managed with medical therapy rather than GAE. Large meniscal tears or loose bodies might need arthroscopic cleanup. Also, patients with severe peripheral arterial disease (poor blood flow to legs) or bleeding disorders might not be good candidates for an arterial procedure. Active infection in the knee is a contraindication as well. Each patient is evaluated carefully to ensure GAE is appropriate.

At Apex Heart & Vascular, we use a multidisciplinary approach: our vascular specialists work closely with orthopedic surgeons, rheumatologists, and pain management physicians. If a patient is a candidate for GAE, we ensure their workup (imaging, etc.) supports that synovial angiogenesis is contributing to their pain, and we coordinate the timing of GAE relative to any other therapies. The goal is always to optimize pain relief and function while minimizing overall risk to the patient.

How GAE Compares to Other Knee Osteoarthritis Treatments

GAE is part of an expanding arsenal of minimally invasive treatments for knee OA. It’s helpful to understand where GAE fits in the treatment spectrum and how it differs from other options. The table below summarizes common treatments for knee osteoarthritis, comparing their approaches, typical duration of benefit, and role:

Key Takeaway: GAE occupies an important middle ground in this spectrum. It is more substantial and longer-acting than a simple injection, yet far less invasive than surgery. It can be performed alongside other measures (for example, a patient could continue physical therapy and occasional NSAIDs after GAE). GAE does not preclude future treatments – if a patient eventually needs a knee replacement, having undergone embolization does not complicate the surgery. In fact, by reducing pain and inflammation, GAE may help patients get by without surgery or stay functional enough to decide on surgery later on on their own terms.

Other emerging therapies include platelet-rich plasma (PRP) injections, stem cell injections, and cryoneurolysis (freezing the nerves), but their long-term efficacy is still under investigation. Compared to these, GAE has a growing evidence base with Level I data and is increasingly being adopted at specialized centers.

Conclusion: A Promising Option for Lasting Knee Pain Relief

Genicular artery embolization is not meant to replace orthopedic surgery when that becomes truly necessary – rather, it bridges the gap between conservative management and total knee replacement. For the many patients who suffer from chronic knee osteoarthritis pain and don’t have good options, GAE offers a new hope: a minimally invasive, safe procedure that can significantly reduce pain, improve mobility, and potentially postpone or even obviate the need for major surgery[48][49].

At Apex Heart & Vascular, Dr. Anuj Shah and our team are proud to be at the forefront of this innovative treatment. We incorporate GAE into a multidisciplinary care plan, ensuring that patients are carefully selected and that the procedure is combined with ongoing joint care (exercise, weight management, etc.) for the best results. Our experience mirrors the published studies – we have seen patients with moderate knee arthritis experience remarkable relief after GAE, regaining the ability to walk longer distances, climb stairs, and enjoy life with significantly less pain.

In grand-rounds style discussions, the consensus is that GAE addresses the vascular driver of pain in osteoarthritis. By embolizing the pathological vessels, we dial down the inflammation and break the pain cycle. For patients, the appeal is clear: no incision, no prosthetic implants, quick recovery, and durable relief. For physicians, GAE represents a paradigm shift where interventional radiology intersects with orthopedics and pain management to treat a musculoskeletal condition from a novel angle.

Medically accurate and evidence-based: The efficacy of GAE is supported by randomized trials (showing meaningful pain reduction beyond placebo) and clinical series with up to 2–3 year follow-ups[12][7]. The procedure has an excellent safety profile, with only minor, transient side effects reported[24]. While not every patient will respond, the vast majority do benefit, and those who respond often have life-changing improvements in pain. Ongoing research will continue to refine patient selection (e.g. using MRI or ultrasound to confirm synovial neovessels) and optimal techniques (particle size, etc.).

In conclusion, Genicular Artery Embolization is a breakthrough therapy giving knee OA patients a much-needed option in the continuum of care. It exemplifies how advances in endovascular science can go beyond traditional vascular diseases to address chronic orthopedic pain conditions. For patients struggling with knee pain who “aren’t bad enough for surgery, but bad enough to be miserable,” GAE can be the difference-maker – offering significant relief, improved function, and a renewed hope for an active life without immediately resorting to joint replacement.

Sources:

• Bagla, S. et al. J Vasc Interv Radiol. 2022;33(1):2–10 – Multicenter RCT of GAE vs sham, showing superior pain and function outcomes with GAE[22][50].
• van Zadelhoff, T.A. et al. BMJ Open. 2024;14(10):e087047 – Double-blind RCT in mild OA (no difference vs sham at 4 months, highlighting importance of patient selection)[29][31].
• Okuno, Y. et al. J Vasc Interv Radiol. 2017;28(7):995–1002 – Prospective study of GAE in 72 patients; ~80% had sustained pain relief at 3 years, with improved MRI synovitis and no osteonecrosis[38][20].
• O’Brien, S. et al. J Clin Med. 2024;13(11):3256 – Narrative review of GAE for knee OA, summarizing multiple studies and outcomes[17][33].
• UCSF Radiology – “Geniculate Artery Embolization: A Minimally Invasive Option to Manage Knee Pain from Osteoarthritis.” (Patient education page, 2025)[51][3].
• Landers, S. et al. Bone Joint Open. 2023;4(3):158–167 – Triple-blind RCT in early OA; subgroup with complete embolization had significant KOOS pain improvement vs sham[26].
• Casadaban, L. et al. Cardiovasc Intervent Radiol. 2020;44(1):1–9 – Systematic review noting sustained VAS pain reductions up to 2 years, especially in moderate OA[34].
• Poursalehian, M. et al. JBJS Rev. 2023;11(3):e23 – Comprehensive review confirming consistent pain score improvements post-GAE and maximal benefit 1–4 months post-procedure[37].

EMBEDDED IMAGE SOURCE: Courtesy of UCSF Department of Radiology; angiographic images of genicular artery embolization before and after, demonstrating pruning of abnormal vessels around the knee[8].

---

[1] [2] [4] [5] [6] [11] [13] [14] [16] [17] [25] [26] [27] [33] [34] [35] [36] [37] [39] [40] Selective Genicular Artery Embolization in the Management of Osteoarthritic Knee Pain—A Narrative Review

https://www.mdpi.com/2077-0383/13/11/3256

[3] [8] [9] [10] [15] [41] [42] [43] [46] [47] [48] [49] [51] Geniculate Artery Embolization (GAE): A Minimally Invasive Option to Manage Knee Pain from Osteoarthritis | UCSF Radiology

https://radiology.ucsf.edu/patient-care/services/geniculate-artery-embolization

[7] [18] [19] [20] [38] Midterm Clinical Outcomes and MR Imaging Changes after Transcatheter Arterial Embolization as a Treatment for Mild to Moderate Radiographic Knee Osteoarthritis Resistant to Conservative Treatment – PubMed

https://pubmed.ncbi.nlm.nih.gov/28365171/

[12] [21] [22] [23] [24] [50] Multicenter Randomized Sham Controlled Study of Genicular Artery Embolization for Knee Pain Secondary to Osteoarthritis – PubMed

https://pubmed.ncbi.nlm.nih.gov/34610422/

[28] Genicular artery embolization for early-stage knee osteoarthritis

https://pubmed.ncbi.nlm.nih.gov/37051829/

[29] [30] [31] [32] (PDF) Genicular artery embolisation versus sham embolisation for symptomatic osteoarthritis of the knee: a randomised controlled trial

https://www.researchgate.net/publication/384542220_Genicular_artery_embolisation_versus_sham_embolisation_for_symptomatic_osteoarthritis_of_the_knee_a_randomised_controlled_trial

[44] Review of genicular artery embolization, radiofrequency ablation …

https://dirjournal.org/articles/review-of-genicular-artery-embolization-radiofrequency-ablation-and-cryoneurolysis-in-the-management-of-osteoarthritis-related-knee-pain/dir.2022.221288

[45] Percutaneous Management of Osteoarthritis in the Knee – JVIR

https://www.jvir.org/article/S1051-0443%2821%2900798-3/pdf